Estimating prevalence for limb-girdle muscular dystrophy based on public sequencing databases.
disease prevalence
limb-girdle muscular dystrophy
rare disease
Journal
Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
07
02
2019
accepted:
02
05
2019
pubmed:
21
5
2019
medline:
28
4
2020
entrez:
21
5
2019
Statut:
ppublish
Résumé
Limb-girdle muscular dystrophies (LGMD) are a genetically heterogeneous category of autosomal inherited muscle diseases. Many genes causing LGMD have been identified, and clinical trials are beginning for treatment of some genetic subtypes. However, even with the gene-level mechanisms known, it is still difficult to get a robust and generalizable prevalence estimation for each subtype due to the limited amount of epidemiology data and the low incidence of LGMDs. Taking advantage of recently published exome and genome sequencing data from the general population, we used a Bayesian method to develop a robust disease prevalence estimator. This method was applied to nine recessive LGMD subtypes. The estimated disease prevalence calculated by this method was largely comparable with published estimates from epidemiological studies; however, it highlighted instances of possible underdiagnosis for LGMD2B and 2L. The increasing size of aggregated population variant databases will allow for robust and reproducible prevalence estimates of recessive disease, which is critical for the strategic design and prioritization of clinical trials.
Identifiants
pubmed: 31105274
doi: 10.1038/s41436-019-0544-8
pii: S1098-3600(21)01069-8
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2512-2520Références
Vissing J. Limb girdle muscular dystrophies: classification, clinical spectrum and emerging therapies. Curr Opin Neurol. 2016;29:635–641.
Nallamilli BRR, Chakravorty S, Kesari A, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol. 2018;5:1574–1587.
Stence A, Westra S, Mathews KD, et al. Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol. 2006;65:995–1003.
Magri F, Nigro V, Angelini C, et al. The Italian Limb Girdle Muscular Dystrophy Registry: relative frequency, clinical features, and differential diagnosis. Muscle Nerve. 2017;55:55–68.
Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord. 1991;1:19–29.
Mazzucato M, Visonà Dalla Pozza L, Manea S, Minichiello C, Facchin P. A population-based registry as a source of health indicators for rare diseases: the ten-year experience of the Veneto Region’s rare diseases registry. Orphanet J Rare Dis. 2014;9:37.
Topaloglu H. Epidemiology of muscular dystrophies in the Mediterranean area. Acta Myol. 2013;32:138–141.
Hicks D, Sarkozy A, Muelas N, et al. A founder mutation in Anoctamin 5 is a major cause of limb girdle muscular dystrophy. Brain. 2011;134:171–182.
Frosk P, Greenberg CR, Tennese AAP, et al. The most common mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred only once and is present in Hutterites and other populations. Hum Mutat. 2004;25:38–44.
Pantoja-Melendez CA, Miranda-Duarte A, Roque-Ramirez B, Zenteno JC. Epidemiological and molecular characterization of a Mexican population isolate with high prevalence of limb-girdle muscular dystrophy type 2A due to a novel calpain-3 mutation. PLoS ONE. 2017;12:e0170280.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405.
Schrodi SJ, DeBarber A, He M, et al. Prevalence estimation for monogenic autosomal recessive diseases using population-based genetic data. Hum Genet. 2015;134:659–669.
Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285.
Angelini C, Grisold W, Nigro V. Diagnosis by protein analysis of dysferlinopathy in two patients mistaken as polymyositis. Acta Myol. 2011;30:185–187.
Sarkozy A, Deschauer M, Carlier R-Y, et al. Muscle MRI findings in limb girdle muscular dystrophy type 2L. Neuromuscul Disord. 2012;22:S122–S129.
Rentzsch P, Kircher M, Witten D, Cooper GM, Shendure J. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2018;47:D886–D894.
Fanin M, Nascimbeni AC, Fulizio L, Angelini C. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul Disord. 2005;15:218–224.
Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132:3175–3186.
Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38:S512–S521.
Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013;3:a011700–a011700.
Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7:450–453.
Rivas MA, Avila BE, Koskela J, et al. Insights into the genetic epidemiology of Crohn’s and rare diseases in the Ashkenazi Jewish population. PLoS Genet. 2018;14:e1007329–e1007329.
Rozenberg R, Pereira LdV. The frequency of Tay–Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program. Sao Paulo Med J. 2001;119:146–149.
Ernst C, Hahnen E, Engel C, et al. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics. BMC Med Genomics. 2018;11:35.
Li J, Zhao T, Zhang Y, et al. Performance evaluation of pathogenicity-computation methods for missense variants. Nucleic Acids Res. 2018;6:7793–7804.
Lehtokari V-L, Greenleaf RS, DeChene ET, et al. The exon 55 deletion in the nebulin gene—one single founder mutation with world-wide occurrence. Neuromuscul Disord. 2009;19:179–181.
Manzini MC, Gleason D, Chang BS, et al. Ethnically diverse causes of Walker–Warburg syndrome (WWS): FCMD mutations are a more common cause of WWS outside of the Middle East. Hum Mutat. 2008;28:E231–41.
Zou J, Valiant G, Valiant P, et al. Quantifying unobserved protein-coding variants in human populations provides a roadmap for large-scale sequencing projects. Nat Commun. 2016;7:13293.
Auvin S, Irwin J, Abi-Aad P, et al. The problem of rarity: estimation of prevalence in rare disease. Value Health. 2018;21:501–507.
Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980–D985.
Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–315.
Urtasun M, Sáenz A, Roudaut C, et al. Limb-girdle muscular dystrophy in Guipúzcoa (Basque Country, Spain). Brain. 1998;121 pt 9:1735–1747.
Tomé FMS, Collin H, Fardeau M, et al. Juvenile limb-girdle muscular dystrophy: clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain. 1996;119:295–308.
Fanin M, Duggan DJ, Mostacciuolo ML, et al. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet. 1997;34:973.
Ben Hamida M, Fardeau M, Attia N. Severe childhood muscular dystrophy affecting both sexes and frequent in Tunisia. Muscle Nerve. 1983;6:469–480.
El Kerch F, Ratbi I, Sbiti A, Laarabi F-Z, Barkat A, Sefiani A. Carrier frequency of the c.525delT mutation in the SGCG gene and estimated prevalence of limb girdle muscular dystrophy type 2C among the Moroccan population. Genet Test Mol Biomarkers. 2014;18:253–256.
Okizuka Y, Takeshima Y, Itoh K, et al. Low incidence of limb-girdle muscular dystrophy type 2C revealed by a mutation study in Japanese patients clinically diagnosed with DMD. BMC Med Genet. 2010;11:49.
Penttilä S, Palmio J, Suominen T, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology. 2012;78:897.
Witting N, Duno M, Petri H, et al. Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression. J Neurol. 2013;260:2084–2093.